Understanding hereditary angioedema (HAE)

Breaking down what plan sponsors should know about HAE, its challenges and therapies.

Lesley D'Albini, PharmD, March 27, 24

The benefits of timely and actionable specialty reporting

A comprehensive suite of reporting tools—and the right specialty partner to interpret data—can be invaluable for plan sponsors.

Viju Paul, RPh, November 20, 23

Two Ways to Assess the Holistic Value of Your Specialty Partner

Getting the most value out of your specialty drug management partner starts with asking the right questions.

Stephanie Uder, October 06, 22

Providing a high level of customization and modularity to third-party administrators and health plans

September 16, 24

Copay Assistance Strategy Reduces Financial Burdens for Plans And Patients

Innovative solution provides $0 member cost for costly specialty drugs while reducing plans’ costs

Meghan Pasicznyk, PharmD, October 07, 21

The importance of a clinical-first approach to formulary development

The clinical efficacy of a drug must always take priority over any other considerations when developing formularies.

Andy Behm, PharmD, BCGP, February 05, 24

Biosimilar Approval and Adoption Challenges

Accelerating the progress of biosimilars is key to lowering drug costs and improving patient access to potentially life-saving therapies.

Harold Carter, PharmD, June 10, 22